Here's my take - also posted on YMB:

Somewhat of a lightweight article - did not even mention that this would necessarily be a basal insulin given the transit time through the gut. In no way can it come close to the pharmacokinetics of Afrezza. No market overlap whatsoever. It may, however, be complimentary to Afrezza in a basal / bolus setting.